EBS News and Press, Emergent Biosolutions Inc. From 11/05/20

Emergent Biosolutions (EBS): Q3 Non-GAAP EPS of $2.19 beats by $0.04; GAAP EPS of $0.73 misses by $1.03.Revenue of $385.2M (+23.5% Y/Y) misses by $53.31M.FY2020 guidance: Total revenues of $1,520M-$1,580M from previous guidance of $1,500M-$1,600M vs consensus of $1.52B ; Adjusted net income o...

Reports strong third quarter and record year to date performance Updates full year guidance — refines revenue ranges and raises profitability ranges GAITHERSBURG, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial result...

Emergent Biosolutions (NYSE:EBS) is scheduled to announce Q3 earnings results on Thursday, November 5th, after market close.The consensus EPS Estimate is $2.15 (+77.7% Y/Y) and the consensus Revenue Estimate is $438.51M (+40.6% Y/Y).Over the last 2 years, EBS has beaten EPS estimates 75% of t...

Emergent BioSolutions has key niche differentiators that strengthen the operating model, with exposure to defence & public health threats. They hold the only FDA approved anthrax vaccine in their portfolio, and ~60% of total revenues are backed by US Government contract agreements...

GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 5, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2020, recent business developments, revenue guidance for ...

Shares of Emergent BioSolutions (NYSE: EBS) were falling 10.3% as of 11:45 a.m. EDT on Tuesday. The drop came after Johnson & Johnson announced that it had paused its late-stage study of coronavirus vaccine candidate JNJ-78436735 because of an unexplained illness with on...

Gainers: Medigus (MDGS) +84%, Altimmune (ALT) +25%, Enlivex Therapeutics (ENLV) +16%, BiondVax Pharmaceuticals (BVXV) +16%, Aileron Therapeutics (ALRN) +15%.Losers: Gossamer Bio (GOSS) -34%, Avenue Therapeutics (ATXI) -17%, Emergent ...

Gossamer Bio (GOSS) -32% after two studies in GB001, Phase 2B LEDA trial in eosinophilic asthma and Phase 2 TITAN trial in chronic rhinosinusitis, failed to meet the primary endpoints.Wah Fu Education (WAFU) -23%.Hexindai (HX) -20%.Medley Management (MDLY) -19%.I...

Catalent produces vaccines developed by biotech companies both in the U.S. and in Europe. Its results have been impacted by COVID-19, but the company has some strong growth drivers and margins are in the double digits. However, there are high capital expenses and operational costs...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Eyes On Stimulus Developments AgainInvestors are still largely focused on new twists and turns with stimulus efforts in the U.S. Last night, President Dona...